-+ 0.00%
-+ 0.00%
-+ 0.00%

Axsome presents new Phase 3 ENCORE trial data for AXS-12 in narcolepsy with cataplexy at SLEEP 2026

PUBT·06/15/2026 11:01:06
Listen to the news
Axsome presents new Phase 3 ENCORE trial data for AXS-12 in narcolepsy with cataplexy at SLEEP 2026
  • Axsome Therapeutics flagged new clinical data for AXS-12 in narcolepsy with cataplexy, scheduled for presentation at SLEEP 2026 on June 15.
  • The ENCORE Phase 3 open-label extension and randomized-withdrawal analysis points to sustained cognitive and functional benefits, supporting differentiation in narcolepsy care.
  • Additional solriamfetol results, also slated for June 15, assess excessive daytime sleepiness across narcolepsy and obstructive sleep apnea using a composite endpoint approach.
  • A separate June 16 poster examines residual cataplexy burden and quality-of-life impacts in narcolepsy, reinforcing unmet need that could shape future positioning.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Axsome Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606150700PRIMZONEFULLFEED9746754) on June 15, 2026, and is solely responsible for the information contained therein.